NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016 08:00 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
company is scheduled to present at the...
NeuroVive presenterar på Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016 08:00 ET
|
NeuroVive Pharmaceutical AB
Lund, den 7 september, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), ett företag inom mitokondriell medicin, meddelar idag att
företaget kommer att presenteras på...
NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016
August 30, 2016 05:32 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, August 30, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
clinical study CiPRICS will be presented...
NeuroVive meddelar att den kliniska studien CiPRICS presenteras på Svenska Thorax-mötet i oktober 2016
August 30, 2016 05:32 ET
|
NeuroVive Pharmaceutical AB
Lund, den 30 augusti, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,
OTCQX: NEVPF), ett företag inom mitokondriell medicin, meddelar idag att den
kliniska studien CiPRICS kommer att...
NeuroVives operative chef Jan Nilsson lämnar bolaget
August 24, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Lund, den 24 augusti, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,
OTCQX: NEVPF), ett företag inom mitokondriell medicin, meddelar idag att dess
operative chef, Jan Nilsson lämnar...
NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company
August 24, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its
Chief Operating Officer, Jan Nilsson...
NeuroVive Pharmaceutical - Interim report January-June 2016
August 18, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Business operations
Important events April-June 2016
· Fully subscribed rights issue amounting to approximately SEK 77.3 million
after issue expenses
· A preclinical TBI program initiated...
NeuroVive Pharmaceutical - Delårsrapport januari-juni 2016
August 18, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Verksamheten
Väsentliga händelser april-juni 2016
· Företrädesemissionen fulltecknades och tillförde bolaget 77,3 miljoner
kronor efter emissionskostnader
· Ett prekliniskt TBI-program inleddes i...
NeuroVive completes 10 percent acquisition of Isomerase Therapeutics
August 15, 2016 07:30 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
second step in the previously announced...
NeuroVive fullföljer 10 procents delförvärv av Isomerase Therapeutics
August 15, 2016 07:30 ET
|
NeuroVive Pharmaceutical AB
Lund, den 15 augusti, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,
OTCQX: NEVPF), ett företag inom mitokondriell medicin, meddelar idag att andra
delen av det sedan tidigare annonserade...